Unity Biotechnology

Unity Biotechnology filed for voluntary dissolution and a plan of liquidation in Delaware, effective Friday. The company entered into a lease termination agreement for office and lab space in South San Francisco, ending the original lease that ran through December 31, 2029 on March 31, 2026, and agreed to roughly $3.65 million in prepayments. It also executed a sublease termination agreement with Initial Therapeutics; the landlord is entitled to 25% of future monetization proceeds up to a maximum of $26.9 million within 24 months after the lease ends. The stock registers have been closed and the common shares are only transferable in narrow exceptions; the stock was already delisted from Nasdaq in August. » More on de.investing.com

Shareholders of Unity Biotechnology voted at an extraordinary general meeting to approve a plan for the company’s complete liquidation and dissolution. The board of directors is now authorized to carry out the liquidation under the approved plan; a quorum of 97.36% was present and the dissolution motion received a majority of the votes. The common stock was delisted from Nasdaq and now trades on the OTC Pink Market (UNBX) at around $0.07 following a share price decline, while the company’s financial position is regarded as weak. » More on de.investing.com

Unity Biotechnology's stock dropped by 45% after NASDAQ announced it would delist the company due to a lack of ongoing business operations and multiple compliance issues. The reasons include significant staff reductions, no revenue generation, and failure to meet equity and minimum price requirements. Unity Biotechnology will not appeal the decision, and trading in its shares will be suspended starting July 9, 2024. » More on de.investing.com